Literature DB >> 27073070

Kleine-Levin Syndrome.

Oliver Sum-Ping1, Christian Guilleminault2.   

Abstract

OPINION STATEMENT: Kleine-Levin Syndrome [KLS] is often under-recognized and also misdiagnosed. When suspicion for KLS is raised, a thorough clinical evaluation should be performed, including detailed history from family members and a neurologic and psychiatric examination. Additional studies may include PSG, EEG, neuroimaging, as well as serological and CSF studies to rule out alternative diagnoses as clinically indicated. After arriving at a diagnosis of KLS, the foundation of care is supportive. Patients and their families should be provided with education about the disease. During symptomatic periods, patients should be allowed to rest at home under caregiver supervision. Caregivers should pay special attention to the patient's eating habits and mood. Patients should not be allowed to drive or operate heavy machinery during these episodes. In between episodes, avoidance of reported triggers, such as alcohol and infection are encouraged as is maintenance of a regular sleep-wake cycle. Pharmacologic therapy has not been well-studied and for most patients is not necessary. For more severe cases, targeted symptomatic therapy, such as modafinil or amantadine for somnolence or risperidone for psychosis may be considered depending on the patient's symptomatology. Lithium has the best data to support its use as a prophylactic agent and for patients with severe or frequent episodes, may be considered.

Entities:  

Keywords:  Hyperphagia; Hypersexuality; Hypersomnia; Hypocretin; Kleine-Levin syndrome; Lithium

Year:  2016        PMID: 27073070     DOI: 10.1007/s11940-016-0409-2

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  42 in total

1.  Observation of a nervous disease attended by disturbed sleep, at times lethargic and at times convulsive. Edmé Chauvot de Beauchêne (1786).

Authors:  Olivier Walusinski
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-09       Impact factor: 10.154

2.  Kleine-Levin syndrome in a female patient.

Authors:  L B Takrani; D Cronin
Journal:  Can Psychiatr Assoc J       Date:  1976-08

3.  Valproic acid for Kleine-Levin syndrome.

Authors:  F E Crumley
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-07       Impact factor: 8.829

4.  Further experience using clarithromycin in patients with Kleine-Levin syndrome.

Authors:  Lynn Marie Trotti; Donald L Bliwise; David B Rye
Journal:  J Clin Sleep Med       Date:  2014-04-15       Impact factor: 4.062

5.  Relationship between Kleine-Levin syndrome and upper respiratory infection in Taiwan.

Authors:  Yu-Shu Huang; Christian Guilleminault; Kuang-Lin Lin; Fang-Ming Hwang; Feng-Yuan Liu; Yen-Ping Kung
Journal:  Sleep       Date:  2012-01-01       Impact factor: 5.849

6.  Serum cytokine levels in Kleine-Levin syndrome.

Authors:  Birgitte Rahbek Kornum; Thomas Rico; Ling Lin; Yu-Shu Huang; Isabelle Arnulf; Poul Jennum; Emmanuel Mignot
Journal:  Sleep Med       Date:  2015-05-15       Impact factor: 3.492

Review 7.  Kleine-Levin syndrome: a systematic review of 186 cases in the literature.

Authors:  I Arnulf; J M Zeitzer; J File; N Farber; E Mignot
Journal:  Brain       Date:  2005-10-17       Impact factor: 13.501

8.  Clinical features of Kleine-Levin syndrome with localized encephalitis.

Authors:  F Fenzi; A Simonati; F Crosato; L Ghersini; N Rizzuto
Journal:  Neuropediatrics       Date:  1993-10       Impact factor: 1.947

Review 9.  Kleine-Levin Syndrome.

Authors:  Isabelle Arnulf
Journal:  Sleep Med Clin       Date:  2015-06

Review 10.  Kleine-Levin syndrome: a review.

Authors:  Mitchell G Miglis; Christian Guilleminault
Journal:  Nat Sci Sleep       Date:  2014-01-20
View more
  1 in total

1.  Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.

Authors:  Kiran Maski; Lynn Marie Trotti; Suresh Kotagal; R Robert Auger; Todd J Swick; James A Rowley; Sarah D Hashmi; Nathaniel F Watson
Journal:  J Clin Sleep Med       Date:  2021-09-01       Impact factor: 4.324

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.